The activation of FXR reduces hepatic monounsaturated and polyunsaturated fatty acid (MUFA and PUFA) levels, which in turn reduces lipid accumulation by reducing bile acid absorption, this mechanism can effectively prevent NAFLD. Here, NR1H4 is linked to metabolic dysfunction-associated steatotic liver disease.